Expert Interview
Discussing the PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2-drug regimen Dovato compared to the 3-drug regimen Biktarvy for the treatment of HIV-1
Ticker(s): GSK, GILDInstitution: Penn Medicine
- Medical Director and Professor of Medicine at Penn Medicine and has been in the practice of both General Internal Medicine and Infectious Diseases for over 35 years.
- Currently manages over 2-3 patients a month with Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea and is very comfortable discussing the phase 2 controlled human infection model (CHIM) study.
- Particular interest in parasitic disorders and International Medicine and has provided care and taught in many countries in a number of different capacities.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
